elecoglipron

all catalysts(0)

nothing on the calendar yet

News(7)

• Myriad catalysts on deck for obesity’s brightest stars as market continues to accelerate
  Current leaders Eli Lilly and Novo Nordisk have cornered the early market for weight loss therapeutics, but several other players, large and small, are bidding for a piece of the potential $200 bil…
  biospace · 1mo ago
• AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blow
  AstraZeneca will push through with its other Phase 3 studies for volrustomig, including in cervical cancer and mesothelioma.
  biospace · 1mo ago
• AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blow
  AstraZeneca will push through with its other Phase 3 studies for volrustomig, including in cervical cancer and mesothelioma.
  biospace · 1mo ago
• Wainua flop narrows AstraZeneca’s path to $80B goal ahead of high-risk readouts
  With a Phase 3 failure denting the rare disease drug’s prospects, AstraZeneca has little room for error as it plots a path toward its ambitious 2030 sales target.
  biospace · 2mo ago
• AstraZeneca’s ‘extensive’ obesity drug push; $125M for ultrasound-aided genetic medicine
  Newly published data convinced AstraZeneca to conduct a sprawling late-stage program for its GLP-1 pill. Elsewhere, Bausch + Lomb will lay off 119 employees and Cartesian boosted its ‘in vivo’ cell…
  biopharma_dive · 3mo ago
• Gilead and Merck’s latest trial success and flop
  AstraZeneca's GLP-1 pill, GSK's $10.6B cancer startup acquisition, and more biotech news from The Readout
  stat · 3mo ago
• STAT+: AstraZeneca’s GLP-1 pill shows promise in obesity, diabetes trials
  AstraZeneca’s GLP-1 pill showed promise in mid-stage obesity and diabetes studies, but it may still be too early to determine how it stacks up against other oral treatments.
  stat · 3mo ago